AC Immune SA
ACIU · XNASCIK 1651625fmd_0FXX64E155P4JM0KT355XXSQKXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 23 periods
Latest annual · FY2025
Millions- Total revenues
- 4
- Operating income
- (69)
- Net income
- (70)
- Free cash flow
- (70)
Latest quarter · Q2 FY2025
Millions- Total revenues
- 1
- Operating income
- (19)
- Net income
- (21)
- Free cash flow
- (17)
Daily close · ACIUIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions2.26 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- -3.2%
- Revenue, 5 yearsFY2020 to FY2025
- -25.4%
- Net income, 5 yearsFY2020 to FY2025
- n/m
AC Immune SA (ACIU) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | CHF 3.6 million | CHF 27.3 million | -86.9% | 20-F 2026-03-13 · proof |
| Operating income | -CHF 69.3 million | -CHF 52.4 million | 20-F 2026-03-13 · proof | |
| Net income | -CHF 70.4 million | -CHF 50.9 million | 20-F 2026-03-13 · proof | |
| Cash from operating activities | -CHF 69.3 million | CHF 65.8 million | -205.2% | 20-F 2026-03-13 · proof |
| Free cash flow | -CHF 70.2 million | CHF 65.3 million | -207.5% | 20-F 2026-03-13 · proof |
| Total assets | CHF 154.3 million | CHF 230.9 million | -33.2% | 20-F 2026-03-13 · proof |
| Total liabilities | CHF 109.4 million | CHF 118.6 million | -7.8% | 20-F 2026-03-13 · proof |
| Cash and cash equivalents | CHF 26.8 million | CHF 36.3 million | -26.1% | 20-F 2026-03-13 · proof |
- What was AC Immune SA (ACIU)'s revenue in fiscal 2025?
- AC Immune SA (ACIU) reported revenue of CHF 3.6 million for fiscal 2025 (the year ended Dec 31, 2025), against CHF 27.3 million the year before (-86.9%). Source: the 20-F filed with the SEC on Mar 13, 2026. SEC
- What was AC Immune SA (ACIU)'s operating income in fiscal 2025?
- AC Immune SA (ACIU) reported operating income of -CHF 69.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -CHF 52.4 million the year before. Source: the 20-F filed with the SEC on Mar 13, 2026. SEC
- What was AC Immune SA (ACIU)'s net income in fiscal 2025?
- AC Immune SA (ACIU) reported net income of -CHF 70.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -CHF 50.9 million the year before. Source: the 20-F filed with the SEC on Mar 13, 2026. SEC
- What was AC Immune SA (ACIU)'s cash from operating activities in fiscal 2025?
- AC Immune SA (ACIU) reported cash from operating activities of -CHF 69.3 million for fiscal 2025 (the year ended Dec 31, 2025), against CHF 65.8 million the year before (-205.2%). Source: the 20-F filed with the SEC on Mar 13, 2026. SEC
- What was AC Immune SA (ACIU)'s free cash flow in fiscal 2025?
- AC Immune SA (ACIU) reported free cash flow of -CHF 70.2 million for fiscal 2025 (the year ended Dec 31, 2025), against CHF 65.3 million the year before (-207.5%). Source: the 20-F filed with the SEC on Mar 13, 2026. SEC
- What are AC Immune SA (ACIU)'s total assets?
- As of Dec 31, 2025, AC Immune SA (ACIU) reported total assets of CHF 154.3 million, against CHF 230.9 million a year earlier (-33.2%). Source: the 20-F filed with the SEC on Mar 13, 2026. SEC
- What are AC Immune SA (ACIU)'s total liabilities?
- As of Dec 31, 2025, AC Immune SA (ACIU) reported total liabilities of CHF 109.4 million, against CHF 118.6 million a year earlier (-7.8%). Source: the 20-F filed with the SEC on Mar 13, 2026. SEC
- What are AC Immune SA (ACIU)'s cash and cash equivalents?
- As of Dec 31, 2025, AC Immune SA (ACIU) reported cash and cash equivalents of CHF 26.8 million, against CHF 36.3 million a year earlier (-26.1%). Source: the 20-F filed with the SEC on Mar 13, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:ACIU&period_type=annual&limit=5"Information only, not investment advice.